Chardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33

Benzinga Newsdesk www.benzinga.com Positive 87.5%

Neg 0% Neu 0% Pos 87.5%

Chardan Capital analyst Keay Nakae maintains ProMIS Neurosciences (NASDAQ:PMN) with a Buy and raises the price target from $20 to $33.